JENKINTOWN, PA — SFA Therapeutics, Inc., a biotech firm specializing in autoimmune diseases and hepatocellular carcinoma, announced a significant expansion of its intellectual property this week. The company secured a new U.S. patent (11963938) and two patent applications in Canada and Korea, extending protection through 2036. Additionally, a new Korean patent (10-2646764) has been issued, covering the technology until 2038.
These patents protect the innovative short chain fatty acid compositions used in SFA’s proprietary compounds, SFA-001 and SFA-002. SFA-001, an oral small-molecule biosynthetic compound, is a potent immunomodulator under evaluation for its efficacy in preventing and treating hepatocellular carcinoma. Preclinical studies have shown its effectiveness against liver cancer cells without harming normal liver tissue. The compound was granted Orphan Drug Designation by the FDA in 2019.
The newly secured patents also cover SFA-002, a Phase-2 ready candidate designed to treat psoriasis by modulating immune pathways. SFA-002 targets pro-inflammatory cytokines and enhances anti-inflammatory responses, aiming to restore immune balance.
Dr. Ira Spector, CEO of SFA Therapeutics, emphasized the importance of the expanded patent portfolio. “As SFA’s clinical development progresses, we understand the importance of strengthening our intellectual property portfolio to protect SFA Therapeutics’ proprietary therapeutic candidates,” he stated.
Dr. Mark Feitelson, Chief Scientific Officer, highlighted the innovative nature of their platform. “These patents demonstrate the novel nature of SFA Therapeutics’ platform and drug candidates which are developed by adding disease-specific adjuvants to compounds that are naturally found in the human body,” he said. The company believes these advancements not only manage symptoms but also address underlying causes of autoimmune conditions.
With these developments, SFA Therapeutics now holds 15 issued and allowed patents, with an additional 33 pending, reinforcing its commitment to advancing treatments for autoimmune and inflammatory diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.